United States
Their expertise aids companies in developing therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval, and commercial release. Cygnus' analytical tools and solutions provide insights to improve bioprocess development for faster regulatory approval and better clinical outcomes.
Established by Ken Hoffman in 1997, Cygnus has a strong reputation for developing and commercializing the first generic assay kits for HCP detection. Their technological advancements, such as the Antibody Affinity Extraction™ (AAE) technology and unique viral clearance approach using non-infectious mock virus particles through its MockV™ virus clearance kits, have set new standards in the industry.
Operating from Southport, North Carolina, Cygnus Technologies is a pioneer in the biopharmaceutical industry. With a track record in quality and innovation, Cygnus continues its commitment to advancing technology to improve biotherapeutic safety and expedite the regulatory approval process. For more information, visit www.cygnustechnologies.com.
